en

PRODUCT DETAIL

Sastravi 150 mg/37,5 mg/200 mg

Code 1219B
MA number 27/0296/14-S
Product Form: tbl flm 30x150 mg/37,5 mg/200 mg (obal HDPE)
MA Status: D - Marketing Authorisation valid for an unlimited period
Type of procedure: Decentralised
Therapeutic Class: 27 - ANTIPARKINSONICA
ATC:
N NERVOUS SYSTEM
N04 ANTI-PARKINSON DRUGS
N04B DOPAMINERGIC AGENTS
N04BA Dopa and dopa derivatives
N04BA03 LEVODOPA, DECARBOXYLASE INHIBITOR AND COMT INH.
Shelf life: 24
Container: HDPE tablet container
Route of admin.: Oral use
Prescription Status: Medicinal product subject to medical prescription.
Legal basis: Article 10(1) generic application
MA issued: 27.08.2014
SPC: SPC_Sastravi_07.2022.pdf  
PIL: PIL_Sastravi_07.2022.pdf  
Safety feature Yes
Data update: 23.11.2020
eu-flag.png sk-flag.png